Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town.

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Amgen's established products also face ongoing competitive pressures. The company must continue to innovate and demonstrate the value of its therapies to maintain market share and drive growth.

Equities research analysts at William Blair reduced their FY2024 earnings per share estimates for shares of Amgen in a ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.

Amgen has several products that should drive top-line growth for many years, including Tepezza, the only medicine for thyroid ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

Fortune Brands recently announced it will consolidate its U.S offices into one headquarters, taking over two of three office ...